Seeking Alpha

Novavax rises on publication of data from A(H7N9) vaccine candidate study

  • Novavax (NVAX) jumps 9% premarket.
  • Wednesday evening, the company announced that The New England Journal of Medicine published what NVAX calls "positive clinical data" from a study of  the VLP A(H7N9) vaccine candidate.
  • Summary: The vaccine was well tolerated, safety was "in-line with previous findings," and 81% and 97% of 5ug adjuvanted vaccine recipients had protective HAI levels and anti-neuraminidase antibody responses, respectively. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|